Merck has announced encouraging Phase 3 results for its investigational cancer therapy sacituzumab tirumotecan (sac-TMT), offering new hope for patients with advanced or recurrent endometrial cancer who have limited treatment options after standard therapies fail.
The company revealed that the global TroFuse-005 clinical trial successfully achieved its two primary goals, improving overall survival (OS) and progression-free survival (PFS), when compared with conventional chemotherapy in previously treated patients.